Redcare Pharmacy stock gains as sector peer DocMorris lifts guidance

Redcare Pharmacy N.V. (ISIN NL0012044747) stock is trading higher on August 19, 2026, with the shares up 2.32 percent at €63.95 in intraday European trading as sector sentiment brightens following stronger results and guidance from a key online pharmacy peer. This move comes one day after the stock fell 2.80 percent, underscoring the recent volatility around European e-pharmacy names.

Redcare Pharmacy shares rebound in active trade

According to a detailed intraday performance overview, Redcare Pharmacy shares are quoted at €63.95 as of August 19, 2026, 10:30 a.m. CET, representing a €1.45 gain versus the previous close. Over the past week, the stock has advanced 6.12 percent, marking a short-term recovery after the prior session’s decline. The current quote sits modestly above the cluster of support levels around €60 identified on August 18, 2026, when shares changed hands near €60.33 on one German trading venue and €60.00 on another, highlighting how the €60 zone has become an important technical reference area for traders. Recent closing data also show a €64.30 level from August 17, 2026, indicating that the latest intraday price remains slightly below that recent high and within a broader support corridor between €53.66 and €60.44. For context further back in the year, one long-run performance snapshot notes that Redcare Pharmacy’s stock opened 2026 at C$75.00 on an OTC listing and, based on a recent quote of C$64.80 cited on August 17, 2026, is down 13.6 percent year to date.

Short-term technical readings from European trading venues indicate that the stock’s recent weakness had pushed it to trade 3.3 percent below its 50-day moving average around August 6, 2026, before the latest rebound. That discount to the medium-term trend line is now narrowing as the price moves back into the low-60-euro range. In addition, a consensus snapshot from a derivatives venue shows a real-time underlying level of €62.50 as of August 19, 2026, with a year-to-date performance reading of plus 3.52 percent and a five-day performance of minus 1.26 percent, illustrating that, while the share price has been volatile, it is modestly higher than at the start of the year on that metric. For investors comparing the current spot price with fundamental expectations, an analyst overview lists a separate consensus level of €61.42 as of August 18, 2026, with a year-to-date change of minus 6.72 percent, underscoring how different trading references can paint slightly different pictures of 2026 performance and why today’s move into the mid-60-euro band stands out.

Peer DocMorris lifts outlook and narrows losses

Sector context plays a central role in today’s move. A fresh report on August 19, 2026, notes that DocMorris, another major European online pharmacy operator, has become more optimistic on its business after reporting improved first-half 2026 numbers. Management has guided for an adjusted EBITDA in the second half of 2026 between minus 10 million and minus 17.5 million Swiss francs, corresponding to a range between CHF -10 million and CHF -17.5 million, which in euro terms is roughly between €10.6 million and €18.6 million in negative adjusted EBITDA. This guidance range, while still pointing to a loss, indicates a narrower expected operating deficit compared with earlier periods and has been cited as evidence that EBITDA breakeven in the second half of 2026 remains within reach.

The same coverage highlights that in the first six months of 2026, DocMorris cut its adjusted operating loss significantly, reducing it from CHF 28.8 million to CHF 10.9 million, a reduction of CHF 17.9 million. Net loss also improved, falling from CHF 61.6 million in the prior-year period to CHF 53.1 million in the first half of 2026. External revenue for DocMorris rose by nearly 10 percent to CHF 628 million in the first half, with the business for prescription medicines accelerating by 38 percent year on year, and the second quarter alone seeing a 46 percent increase in that segment. In equity markets, DocMorris shares responded positively, climbing more than 6 percent on the Tradegate platform to €10.88 versus the prior Zurich close, with intraday gains that at one point reached 12 percent. This strong reaction has helped pull the broader e-pharmacy space higher, with one note explicitly stating that Redcare Pharmacy shares added 2 percent in the slipstream of DocMorris’ rally.

Additional data on DocMorris’ stock from another performance table show that the shares closed at CHF 9.630 on the Swiss Exchange on August 18, 2026, representing a five-day change of minus 1.58 percent and a year-to-date gain of 61.85 percent. An analyst consensus compiled around the same time assigns an average target price of CHF 10.22, implying a 6.11 percent upside from the last close, which helps explain why the market reacted strongly to the latest earnings release. The earnings disclosure on August 18, 2026, is labeled as the Q2 2026 release, confirming that the revenue and loss metrics cited are current within the freshness window relative to August 19, 2026. For Redcare Pharmacy investors, the combination of improving peer fundamentals and positively received guidance provides a supportive backdrop for sentiment toward the broader online pharmacy segment.

Analyst expectations and valuation framework for Redcare

While the latest earnings and guidance for Redcare Pharmacy itself are not detailed in today’s source set, an analyst consensus panel delivers a structured view of expectations and valuation benchmarks as of August 18 and August 19, 2026. One derivatives-linked consensus screen on August 19, 2026, shows a reference level of €62.50 for Redcare Pharmacy, a five-day performance reading of minus 1.26 percent, a year-to-date change of plus 3.52 percent, and a change since January 1 of minus 3.95 percent. These figures suggest that, according to that reference, the stock has given up a few percentage points over the last week but still sits modestly higher than at the start of the year, even as the longer year-to-date performance metric retains a small negative bias.

A separate analyst overview compiled as of August 18, 2026, lists a current underlying price of €61.42 for Redcare Pharmacy, with the five-day change recorded as flat and the year-to-date change at minus 6.72 percent, indicating that this particular metric sees the stock lower in 2026 compared with where it began the year. Crucially for valuation, the same consensus panel reports an average target price of €62.85, a high target of €116.00, and a low target of €55.00. The spread between the current underlying level of €61.42 and the average target of €62.85 is €1.43, meaning analysts collectively see limited upside from that specific reference price in the near term but acknowledge a very wide range of scenarios, with some forecasts stretching to nearly double the current level while others sit modestly below it. For investors, these metrics offer a quantitative framework to compare the intraday spot price of €63.95 with where consensus currently stands, suggesting the stock is trading slightly above the average target but far below the highest expectations.

In addition to price-based measures, the consensus tables often include indicators such as revisions and momentum flags. Although detailed revisions are not spelled out in full, the recent five-day and year-to-date performance readings and the relatively tight spread to the average target underscore that, at least based on the data provided, analysts view Redcare Pharmacy as a company that has already priced in a substantial portion of its growth story in the short term. However, the upper target of €116.00 hints at a longer-term thesis among bullish analysts who expect significant value creation if the company continues to expand its European market share and improves profitability in line with trends seen at peers like DocMorris. Investors may therefore focus on how upcoming quarterly numbers for Redcare Pharmacy align with these expectations, particularly around revenue growth in prescription medicine, margin progression, and the path toward sustainable positive EBITDA.

Redcare Pharmacy’s online pharmacy offering

Redcare Pharmacy’s core business model centers on a digitally enabled mail-order and online pharmacy platform targeting customers across Europe. The company offers a broad range of products to consumers, including prescription medicines where regulation allows, over-the-counter drugs, personal care items, wellness products, and health-related consumer goods. A corporate profile page notes the company’s address in Sevenum and points to an official website, indicating a focus on building a recognizable brand presence and a strong logistical backbone to support rapid delivery. The mail-order structure allows customers to order medications and health products from home, with the company handling prescription validation and shipping, which can be particularly attractive in markets where e-prescription adoption is increasing and national health systems encourage digital channels.

Competitive dynamics in European online pharmacy markets are intense, with players such as DocMorris and other digital health providers pushing aggressively into prescription segments. Recent data on DocMorris’ prescription medicine sales, which grew 38 percent year on year in the first half of 2026 and 46 percent in the second quarter alone, illustrate the scale of demand moving into online channels. For Redcare Pharmacy, this environment creates both opportunities and pressures. Opportunities include tapping into rising consumer comfort with ordering medicines online, leveraging e-prescriptions, and expanding cross-border offerings where regulation permits. Pressures include maintaining attractive pricing, navigating reimbursement frameworks, and investing in technology and logistics to support growth without eroding margins. As investors assess Redcare’s prospects, the performance of peers and sector-wide trends in prescription volume and revenue provide valuable benchmarks.

Shares trade in the low-60-euro band on German venues

Redcare Pharmacy is listed on the Xetra platform in Germany under the ticker RDC.DE, with additional trading on venues such as Lang & Schwarz, Tradegate, and other regional exchanges. A recent quote snapshot from August 18, 2026, shows the stock trading at €60.33 on Lang & Schwarz at 10:35 a.m. CET, with nearly 10,000 shares changing hands in that snapshot, while Xetra recorded a €60.00 quote for the stock in the same timeframe. These levels, taken together with the €64.30 Tradegate closing indication from August 17, 2026, emphasize that the shares have been oscillating within a relatively tight low-to-mid-60-euro range in recent sessions. One technical summary identifies a support corridor between €53.66 and €60.44, meaning the current intraday price of €63.95 on August 19, 2026, sits above that corridor but still close enough that traders watch the €60 line as a key threshold.

Market data from the OTC listing for Redcare Pharmacy under the symbol SHPPF provide an additional perspective. As of August 17, 2026, the stock’s OTC quote stands at C$64.80, unchanged on the day, with historical data indicating that the shares traded at C$75.00 at the beginning of 2026. This implies a decline of 13.6 percent year to date on that line, which contrasts with the modest year-to-date gains suggested by the €62.50 reference level’s 3.52 percent increase. The divergence between these metrics highlights the importance of understanding which listing and currency an investor uses as their primary reference. For European retail investors trading on Xetra, the low-60-euro range and the support corridor below €60 are crucial technical markers. For investors holding the OTC instrument, the Canadian dollar performance underscores that the stock has yet to reclaim its opening-2026 level despite recent rebounds.

On June 16 and June 17, 2026, another set of quote data captured prices around €61.25 on Xetra, with various regional exchanges posting prices between €61.10 and €61.85 and modest trading volumes, reinforcing a picture of a stock that has spent much of mid-2026 consolidating around the low-60-euro band. The consistency of these readings suggests that, ahead of the next earnings release, the market has been waiting for fresh fundamental catalysts to break the stock out of this range decisively. Against this backdrop, today’s 2.32 percent intraday gain to €63.95 reflects both sector tailwinds from DocMorris’ results and investors’ willingness to position for potential upside in Redcare Pharmacy as broader online pharmacy adoption accelerates.

Read more

For additional context on Redcare Pharmacy’s share performance, including detailed chart data and multi-venue quotes, investors can consult market-data pages that track the stock’s Xetra listing and related German trading platforms, as well as OTC references where available. These resources often provide interactive charts, historical data tables, and analytics such as moving averages and volume trends that complement the snapshot figures cited here.

Representative online pharmacy service

A representative offering in Redcare Pharmacy’s portfolio is its online prescription and over-the-counter medicine ordering service, accessible via the company’s main website. This service allows customers to upload or transmit e-prescriptions for eligible medicines, browse a catalog of non-prescription health products, and complete purchases through a secure digital interface. The platform is designed to integrate with national healthcare systems where e-prescriptions are supported, enabling streamlined verification and fulfillment. Customers benefit from home delivery, transparent pricing, and the ability to compare products and read guidance information online, while Redcare leverages centralized logistics and inventory management to serve multiple European markets from its hubs.

Such a service is emblematic of broader trends in digital health, where traditional pharmacy functions are increasingly migrating online. The strong growth in prescription medicine revenue reported by DocMorris in the first half of 2026 underscores how quickly consumers and healthcare providers are embracing online channels. For Redcare Pharmacy, expanding and refining its own online prescription and OTC service will likely be central to its growth strategy, with key performance indicators including customer acquisition, repeat purchase rates, order volumes, and the mix between prescription and non-prescription items. Investors tracking the stock may therefore pay close attention to future disclosures that quantify these metrics, as they will shed light on how effectively the company is capitalizing on the secular shift toward digital healthcare delivery.

Redcare Pharmacy stock price snapshot

As of August 19, 2026, the most recent intraday performance overview indicates that Redcare Pharmacy stock is trading at €63.95, up 2.32 percent on the day and €1.45 above the prior close, within the low-to-mid-60-euro band that has characterized recent sessions. This level sits modestly above the €62.50 derivatives-linked reference and the €61.42 analyst consensus underlying price, while remaining below the €64.30 Tradegate indication from August 17, 2026. For investors, this combination of spot price, support corridor between €53.66 and €60.44, and consensus targets ranging from €55.00 to €116.00 offers a structured view of the stock’s current technical and valuation landscape as the market digests stronger sector signals from peers and awaits Redcare Pharmacy’s next set of earnings.

Fact box

Company: Redcare Pharmacy N.V.
ISIN: NL0012044747
Ticker: RDC.DE
Exchange: Xetra
Price (as of August 19, 2026, 10:30 a.m. CET): €63.95
Sector / Industry: Health care, retail, mail-order pharmacy